ES2133807T3 - Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. - Google Patents
Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.Info
- Publication number
- ES2133807T3 ES2133807T3 ES95933489T ES95933489T ES2133807T3 ES 2133807 T3 ES2133807 T3 ES 2133807T3 ES 95933489 T ES95933489 T ES 95933489T ES 95933489 T ES95933489 T ES 95933489T ES 2133807 T3 ES2133807 T3 ES 2133807T3
- Authority
- ES
- Spain
- Prior art keywords
- therapeutic use
- peptidyl compounds
- inhibitors
- metaloprotease
- metaloprotease inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPUESTOS DE FORMULA GENERAL (I) TIENEN UTILIDAD COMO INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y TFN.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9420057A GB9420057D0 (en) | 1994-10-05 | 1994-10-05 | Compounds |
| GBGB9504907.8A GB9504907D0 (en) | 1995-03-10 | 1995-03-10 | Compounds |
| GBGB9509431.4A GB9509431D0 (en) | 1995-05-10 | 1995-05-10 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2133807T3 true ES2133807T3 (es) | 1999-09-16 |
Family
ID=27267412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95933489T Expired - Lifetime ES2133807T3 (es) | 1994-10-05 | 1995-10-05 | Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US5994312A (es) |
| EP (1) | EP0784629B1 (es) |
| JP (1) | JP3787605B2 (es) |
| CN (1) | CN1193978A (es) |
| AT (1) | ATE179431T1 (es) |
| AU (1) | AU695796B2 (es) |
| BR (1) | BR9509237A (es) |
| CA (1) | CA2201639A1 (es) |
| CZ (1) | CZ288436B6 (es) |
| DE (1) | DE69509401T2 (es) |
| DK (1) | DK0784629T3 (es) |
| ES (1) | ES2133807T3 (es) |
| FI (1) | FI971412L (es) |
| GR (1) | GR3030751T3 (es) |
| HU (1) | HUT77282A (es) |
| MX (1) | MX9702487A (es) |
| NO (1) | NO971537L (es) |
| PL (1) | PL183510B1 (es) |
| WO (1) | WO1996011209A1 (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU706064B2 (en) * | 1995-05-10 | 1999-06-10 | Darwin Discovery Limited | Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use |
| CA2219973A1 (en) * | 1995-05-10 | 1996-11-14 | Chiroscience Limited | Peptidyl compounds and their therapeutic use |
| ATE226592T1 (de) * | 1995-05-10 | 2002-11-15 | Darwin Discovery Ltd | Peptide, die metallproteinasen und die tnf- freisetzung hemmen, und ihre therapeutische verwendung |
| EP0824544B1 (en) * | 1995-05-10 | 2003-04-16 | Darwin Discovery Limited | Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use |
| KR980009238A (ko) * | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
| KR100472752B1 (ko) * | 1995-10-05 | 2006-01-27 | 다윈 디스커버리 리미티드 | 금속단백질 가수분해 효소 및 티엔에프 유리에 대한 억제제로서의 티오-치환펩티드 |
| GB9523066D0 (en) * | 1995-11-10 | 1996-01-10 | Chiroscience Ltd | Compounds and their therapeutic use |
| AU711907B2 (en) * | 1995-11-22 | 1999-10-21 | Darwin Discovery Limited | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumor necrosis factor (TNF) |
| US6919375B1 (en) | 1996-01-23 | 2005-07-19 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
| HU226006B1 (en) | 1996-01-23 | 2008-02-28 | Shionogi & Co | Thiophene-sulfonylamino carboxylic and hidroxamic acid derivatives and pharmaceutical compositions with metalloproteinase inhibitory activity containing the same |
| GB9607120D0 (en) * | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| US6811995B1 (en) * | 1996-04-26 | 2004-11-02 | Children's Medical Center Corporation | Non-invasive enzyme screen for cancer |
| US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
| ES2194209T3 (es) * | 1996-07-22 | 2003-11-16 | Monsanto Co | Inhibidores de metaloproteasa de tiol sulfona. |
| CN1238688A (zh) * | 1996-07-22 | 1999-12-15 | 孟山都公司 | 硫羟磺酰胺金属蛋白酶抑制剂 |
| GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
| WO1998007421A1 (en) * | 1996-08-16 | 1998-02-26 | Ishihara Sangyo Kaisha, Ltd. | Medicinal composition |
| AU713133B2 (en) * | 1996-08-28 | 1999-11-25 | Shionogi & Co., Ltd. | Novel peptide derivatives having thiazolyl-alanine residue |
| NZ334490A (en) * | 1996-09-19 | 2000-08-25 | Hoechst Marion Roussel Inc | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives as inhibitors of matrix metalloproteinase |
| US6953788B1 (en) | 1996-09-19 | 2005-10-11 | Aventis Pharmaceuticals Inc. | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase |
| GB9624817D0 (en) * | 1996-11-28 | 1997-01-15 | British Biotech Pharm | Metalloproteinase inhibitors |
| EP1366765A1 (en) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| DK0946166T3 (da) * | 1996-12-17 | 2004-05-03 | Warner Lambert Co | Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling |
| EP0981366B1 (en) * | 1997-03-03 | 2004-01-21 | Darwin Discovery Limited | Selective mmp inhibitors having reduced side-effects |
| WO1998039315A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| DK0973392T3 (da) | 1997-03-04 | 2004-03-29 | Monsanto Co | Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser |
| US6696449B2 (en) | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| US6476027B1 (en) | 1997-03-04 | 2002-11-05 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
| US6034136A (en) | 1997-03-20 | 2000-03-07 | Novartis Ag | Certain cyclic thio substituted acylaminoacid amide derivatives |
| US5756545A (en) * | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
| WO1999007679A1 (en) * | 1997-08-08 | 1999-02-18 | Chiroscience Limited | Peptidyl compounds having mmp and tnf inhibitory activity |
| US6319902B1 (en) | 1997-08-22 | 2001-11-20 | Shionogi & Co., Ltd. | Peptide derivatives having thiazolyl-alanine residue |
| US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| EP1042290A1 (en) | 1997-11-14 | 2000-10-11 | G.D. SEARLE & CO. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| FI980604A0 (fi) | 1998-03-18 | 1998-03-18 | Univ Helsinki Licensing | Nya matrismetalloproteinasinhibitorer och -regulatorer |
| CA2347911A1 (en) * | 1998-10-23 | 2000-05-04 | Darwin Discovery Limited | Single morphic forms of known peptide metalloproteinase inhibitors |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
| US6486193B2 (en) * | 1998-12-31 | 2002-11-26 | Aventis Pharmaceuticals Inc. | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases |
| DE69905621T2 (de) * | 1998-12-31 | 2003-11-27 | Aventis Pharmaceuticals Inc., Bridgewater | 3-(thio-substituierte amido)-lactame, verwendbar als inhibitoren der matrix-metalloproteinase |
| US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
| HRP20010660A2 (en) | 1999-02-08 | 2005-02-28 | G.D. Searle & Co | Sulfamato hydroxamic acid metalloprotease inhibitor |
| US6583299B1 (en) | 1999-05-20 | 2003-06-24 | G.D. Searle & Co. | α-amino-β-sulfonyl hydroxamic acid compounds |
| NL1013404C2 (nl) * | 1999-10-27 | 2001-05-01 | Dsm Nv | Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze. |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| ES2208595T3 (es) | 2000-05-15 | 2004-06-16 | Darwin Discovery Limited | Derivados del acido hidroxamico. |
| EP1695703B1 (en) * | 2000-08-25 | 2010-08-11 | Research Corporation Technologies, Inc. | Anticonvulsant amino acids for the treatment of obsessive-compulsive neurosis |
| JP4817281B2 (ja) | 2000-08-31 | 2011-11-16 | 塩野義製薬株式会社 | パーキンソン病治療剤 |
| PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| EP1243263B1 (en) * | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| FR2823212B1 (fr) * | 2001-04-10 | 2005-12-02 | Inst Nat Sante Rech Med | Inhibiteurs de la toxine botulique de type b |
| CA2446586A1 (en) | 2001-05-11 | 2002-11-21 | Thomas E. Barta | Aromatic sulfone hydroxamates and their use as protease inhibitors |
| PL222211B1 (pl) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza |
| US6683078B2 (en) | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| AU2003221786A1 (en) | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| BR0312036A (pt) * | 2002-06-25 | 2005-04-05 | Pharmacia Corp | ácido arilsulfonilhidroxâmico e derivados de amida bem como composição farmacêutica contendo os mesmos e uso dos mesmos |
| BR0317715A (pt) * | 2002-12-27 | 2005-11-22 | Angiotech Int Ag | Composições e processos de uso de collajolie |
| JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
| US20040259744A1 (en) * | 2003-12-19 | 2004-12-23 | Meidong Yang | Skin and hair cleansers containing sulfur |
| CA2562937A1 (en) | 2004-04-16 | 2005-10-27 | Schwarz Pharma Ag | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
| DE602005021970D1 (de) | 2004-08-27 | 2010-08-05 | Ucb Pharma Gmbh | Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
| CN102846601B (zh) | 2006-06-15 | 2015-04-29 | 优时比制药有限公司 | 具有协同抗惊厥作用的药物组合物 |
| WO2008029168A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| WO2009048541A2 (en) * | 2007-10-05 | 2009-04-16 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| EP2990051B1 (en) | 2009-04-10 | 2016-10-26 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
| WO2013016531A2 (en) * | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| WO2013039851A1 (en) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
| CN110143892B (zh) * | 2019-06-21 | 2022-08-12 | 江苏豪森药业集团有限公司 | 莫沙必利中间体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4113715A (en) * | 1977-01-17 | 1978-09-12 | E. R. Squibb & Sons, Inc. | Amino acid derivatives |
| US4235885A (en) * | 1979-06-25 | 1980-11-25 | E. R. Squibb & Sons, Inc. | Inhibitors of mammalian collagenase |
| US4263293A (en) * | 1980-05-30 | 1981-04-21 | E. R. Squibb & Sons, Inc. | Heterocyclic containing amides as inhibitors of mammalian collagenase |
| US4382081A (en) * | 1981-06-12 | 1983-05-03 | E. R. Squibb & Sons, Inc. | Inhibitors of mammalian collagenase |
| GB8311286D0 (en) * | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| EP0358660B1 (en) * | 1987-03-17 | 1994-05-25 | Research Corporation Technologies, Inc. | Synthetic inhibitors of mammalian collagenase |
| AU2228292A (en) * | 1991-06-14 | 1993-01-12 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
| FR2679564A1 (fr) * | 1991-07-23 | 1993-01-29 | Inst Nat Sante Rech Med | Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent. |
| FI960803L (fi) * | 1993-08-23 | 1996-04-22 | Immunex Corp | TNF-alfa-sekreetion inhibiittoreita |
| US5455262A (en) * | 1993-10-06 | 1995-10-03 | Florida State University | Mercaptosulfide metalloproteinase inhibitors |
| GB9323165D0 (en) * | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
-
1995
- 1995-10-05 BR BR9509237A patent/BR9509237A/pt not_active Application Discontinuation
- 1995-10-05 ES ES95933489T patent/ES2133807T3/es not_active Expired - Lifetime
- 1995-10-05 EP EP95933489A patent/EP0784629B1/en not_active Expired - Lifetime
- 1995-10-05 DK DK95933489T patent/DK0784629T3/da active
- 1995-10-05 AT AT95933489T patent/ATE179431T1/de not_active IP Right Cessation
- 1995-10-05 CN CN95195544A patent/CN1193978A/zh active Pending
- 1995-10-05 DE DE69509401T patent/DE69509401T2/de not_active Expired - Fee Related
- 1995-10-05 CZ CZ1997996A patent/CZ288436B6/cs not_active IP Right Cessation
- 1995-10-05 CA CA002201639A patent/CA2201639A1/en not_active Abandoned
- 1995-10-05 MX MX9702487A patent/MX9702487A/es not_active IP Right Cessation
- 1995-10-05 HU HU9702222A patent/HUT77282A/hu unknown
- 1995-10-05 PL PL95319503A patent/PL183510B1/pl unknown
- 1995-10-05 FI FI971412A patent/FI971412L/fi not_active IP Right Cessation
- 1995-10-05 JP JP51241696A patent/JP3787605B2/ja not_active Expired - Fee Related
- 1995-10-05 AU AU36127/95A patent/AU695796B2/en not_active Ceased
- 1995-10-05 WO PCT/GB1995/002362 patent/WO1996011209A1/en not_active Ceased
-
1997
- 1997-04-04 NO NO971537A patent/NO971537L/no unknown
-
1998
- 1998-07-30 US US09/124,877 patent/US5994312A/en not_active Expired - Fee Related
-
1999
- 1999-05-20 US US09/315,279 patent/US6180611B1/en not_active Expired - Fee Related
- 1999-07-14 GR GR990401836T patent/GR3030751T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO971537L (no) | 1997-06-04 |
| US6180611B1 (en) | 2001-01-30 |
| EP0784629A1 (en) | 1997-07-23 |
| DK0784629T3 (da) | 1999-10-25 |
| BR9509237A (pt) | 1997-10-21 |
| JP3787605B2 (ja) | 2006-06-21 |
| FI971412A0 (fi) | 1997-04-04 |
| CN1193978A (zh) | 1998-09-23 |
| ATE179431T1 (de) | 1999-05-15 |
| PL319503A1 (en) | 1997-08-18 |
| DE69509401T2 (de) | 1999-08-19 |
| CZ288436B6 (en) | 2001-06-13 |
| AU695796B2 (en) | 1998-08-20 |
| FI971412A7 (fi) | 1997-04-04 |
| CZ99697A3 (en) | 1997-09-17 |
| GR3030751T3 (en) | 1999-11-30 |
| HUT77282A (hu) | 1998-03-30 |
| US5994312A (en) | 1999-11-30 |
| DE69509401D1 (de) | 1999-06-02 |
| MX9702487A (es) | 1998-04-30 |
| CA2201639A1 (en) | 1996-04-18 |
| AU3612795A (en) | 1996-05-02 |
| WO1996011209A1 (en) | 1996-04-18 |
| PL183510B1 (pl) | 2002-06-28 |
| NO971537D0 (no) | 1997-04-04 |
| FI971412L (fi) | 1997-04-04 |
| EP0784629B1 (en) | 1999-04-28 |
| JPH10507170A (ja) | 1998-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2133807T3 (es) | Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. | |
| MX9700557A (es) | Dihidrobenzofuranos. | |
| ES2170252T3 (es) | Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde. | |
| ES2124793T3 (es) | Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores. | |
| PT991619E (pt) | Inibidores da adesao celular mediada pela alfa4beta1 | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| UY26082A1 (es) | Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica | |
| FI961976A7 (fi) | Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina | |
| DK1039912T3 (da) | Angiostatiske midler og præparater til behandling af GLC1A-glaukom | |
| AR010062A1 (es) | Nuevos benzamidaldehidos y su utilizacion | |
| PT1140944E (pt) | Derivados de epotilona e sua utilizacao como agentes antitumorais | |
| ITMI942025A0 (it) | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia | |
| ES2194106T3 (es) | .ompuestos de imidazol | |
| IT1285770B1 (it) | Composti corticoidei | |
| ATE126215T1 (de) | Anti-entzündende 4-aminophenol-derivate. | |
| MX9302931A (es) | Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa. | |
| ATE433963T1 (de) | Fab-i inhibitoren | |
| DE60129829D1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| FI964936L (fi) | Bentsopyraaneja ja niiden käyttö terapeuttisina aineina | |
| AR020563A1 (es) | Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion | |
| DK1294732T3 (da) | Ruthenium (II)-forbindelser til anvendelse i cancerterapi | |
| BG100248A (bg) | Инхибитори на скваленсинтетаза | |
| DE69612056D1 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel | |
| ATE165594T1 (de) | Triarylethylenderivate zur therapeutischen verwendung | |
| ES2122034T3 (es) | Difosfatos de catecolaminas y composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 784629 Country of ref document: ES |